Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid  deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the Company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.